Drugs / M-CENK
M-CENK
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04898543 | Jun 2021 → May 2026 overdue | metastatic neoplasm | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06765902 | Dec 2025 → Jan 2031 | prostate cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06765954 | Dec 2025 → Jan 2031 | prostate cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06710288 | Nov 2024 → May 2027 expected | refractory malignant neoplasm | ImmunityBio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-13 | ImmunityBio, Inc. | Results ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors immunitybio.com ↗
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy platform. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-13 | ImmunityBio, Inc. | ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors immunitybio.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-CENK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06765902 ↗ |
| Known as | Autologous Memory Cytokine-Enriched NK Cells | “M-CENK (Autologous Memory Cytokine-Enriched NK Cells): These are the patient's own NK cells that are collected through apheresis, expanded and activated ex vivo using cytokines...” NCT06765902 ↗ |
| Known as | cytokine-induced memory-like NK cells | “M-CENK (cytokine-induced memory-like NK cells): Autologous natural killer (NK) cells expanded and modified ex vivo using a cytokine cocktail (IL-12, IL-15, and IL-18) to...” NCT06765954 ↗ |
| Modality | Cell therapy | “M-CENK cells, manufactured from the autologous apheresis product” NCT04898543 ↗ |
| Route | Intravenous | “M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion” NCT04898543 ↗ |